These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16224736)

  • 41. [The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview].
    Sevecke K; Battel S; Dittmann RW; Lehmkuhl G; Döpfner M
    Nervenarzt; 2006 Mar; 77(3):294, 297-300, 302-4 passim. PubMed ID: 16133434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of attention deficit hyperactivity disorder in adults.
    Greenfield B; Hechman L
    Expert Rev Neurother; 2005 Jan; 5(1):107-21. PubMed ID: 15853481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
    Corman SL; Fedutes BA; Culley CM
    Am J Health Syst Pharm; 2004 Nov; 61(22):2391-9. PubMed ID: 15581262
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder.
    Staller JA; Faraone SV
    Expert Rev Neurother; 2007 Apr; 7(4):351-62. PubMed ID: 17425490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drugs under investigation for attention-deficit hyperactivity disorder.
    Schweitzer JB; Holcomb HH
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1207-11. PubMed ID: 12211416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Innovations and recent trends in the treatment of ADHD.
    Madaan V; Kinnan S; Daughton J; Kratochvil CJ
    Expert Rev Neurother; 2006 Sep; 6(9):1375-85. PubMed ID: 17009924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
    Allen AJ; Kurlan RM; Gilbert DL; Coffey BJ; Linder SL; Lewis DW; Winner PK; Dunn DW; Dure LS; Sallee FR; Milton DR; Mintz MI; Ricardi RK; Erenberg G; Layton LL; Feldman PD; Kelsey DK; Spencer TJ
    Neurology; 2005 Dec; 65(12):1941-9. PubMed ID: 16380617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dyskinesias associated with atomoxetine in combination with other psychoactive drugs.
    Bond GR; Garro AC; Gilbert DL
    Clin Toxicol (Phila); 2007; 45(2):182-5. PubMed ID: 17364639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Bases for the selection of pharmacological treatment in attention deficit hyperactivity disorder].
    Soutullo C; Alvarez-Gomez MJ
    Rev Neurol; 2013 Feb; 56 Suppl 1():S119-29. PubMed ID: 23446713
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.
    Prince J
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S39-45. PubMed ID: 18480676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test.
    Navarra R; Graf R; Huang Y; Logue S; Comery T; Hughes Z; Day M
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):34-41. PubMed ID: 17714843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.
    Wernicke JF; Holdridge KC; Jin L; Edison T; Zhang S; Bangs ME; Allen AJ; Ball S; Dunn D
    Dev Med Child Neurol; 2007 Jul; 49(7):498-502. PubMed ID: 17593120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Attention-deficit/hyperactivity disorder: medication treatment-dosing and duration of action.
    Steinhoff KW
    Am J Manag Care; 2004 Jul; 10(4 Suppl):S99-106. PubMed ID: 15352536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A new paradigm for developing drugs in children: atomoxetine as a model.
    Prasad S
    Arch Dis Child; 2005 Feb; 90 Suppl 1(Suppl 1):i13-6. PubMed ID: 15665150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adderall XR: long acting stimulant for single daily dosing.
    Sallee FR; Smirnoff AV
    Expert Rev Neurother; 2004 Nov; 4(6):927-34. PubMed ID: 15853519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risks and benefits of available treatments for adult ADHD.
    Newcorn JH
    J Clin Psychiatry; 2011 Mar; 72(3):e12. PubMed ID: 21450148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Basics of the drug therapy for attention deficit hyperactivity disorders in adolescents].
    Airaksinen E; Airaksinen MM
    Duodecim; 2003; 119(16):1553-62. PubMed ID: 14535028
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.